Clinical analysis of CD5+diffuse large B-cell lymphoma
ZANG Li
LI Xiang-li
ZHANG Xiao-ying
YANG Hong-liang
ZHAO Hai-feng
YU Yong
WANG Ya-fei
ZHAO Zhi-gang
ZHANG yi-zhuo
WANG Xiao-fang
Abstract：Objective To investigate the clinical features and immunophenotype of primary CD5+diffuse large B-cell lym-phoma (DLBCL) and to explore the treatment and prognosis.Methods The clinical data of 33 cases of CD5+DLBCL patients were retrospectively analyzed, The immunephenotype was detected by immunohistochemistry, and their relationship with clinico-pathological features was analyzed.Results There were 16 patients whose age was over 60 years, 19 cases of patients were in the Ann-Arbor stageⅢ-Ⅳ, and there were 3 cases of early onset of bone marrow involvement;IPI score ≥2 were found in 18 cases;CD5 and CD20 were expressed in all patients, and there were 18 cases of patients with positive Bcl-6 expression, 22 cases of Mum-1 positive expression.Both were not related with the patients'age, gender, Ann-Arbor stage, B symptoms and IPI scores (all P<0.05).Except that 5 cases gave up treatment, the majority of patients received the chemotherapy with cyclophospha-mide, doxorubicin, vincristine, CHOP or R-CHOP.The treatment efficacy evaluation were as follows:nine cases with complete remission, 13 cases with partial remission, 3 cases with stability and 3 cases in the progression.Twelve patients relapsed in two years or died in the disease progression, including 4 cases of central nervous system involvement and death.The median survival was 17.8 months, and 2-year overall survival rate was 53.9%.Conclusions Primary CD5+DLBCL is more common in older pa-tients with poor prognosis, and it is easy to have central and bone marrow involvement, with high degree of malignancy, mean-while, the efficacy of CHOP or R-CHOP is not good.Histopathological tissues are mostly from the non-germinal center.In addi-tion, the Bcl-6 and Mum-1 expression is not related with the clinicopathologic features and prognosis of CD 5+DLBCL.
Keywords：diffuse large B-cell lymphomaCD5+immunohistochemistryelderly female
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 12-14 )